SCHEMBL207608

SCHEMBL207608

Cc1cccc(CC2(N(C)C)CCC(NC(=O)CCC(=O)NCCc3c[nH]c4ccccc34)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCHE P06276 5/20 0.56
ACHE P22303 5/20 0.56
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
RECQL P46063 1/20 0.52
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MTNR1A P48039 2/20 0.48
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
MAPK1 P28482 1/20 0.46
PTGS2 P35354 2/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.45
PTGS1 P23219 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206020 0.91 ACHE (0.53) BCHEACHEHPGDHTTRECQL
SCHEMBL208507 0.90 ACHE (0.59) BCHEACHEHPGDMEN1KMT2A
SCHEMBL208032 0.89 CDK4 (0.50) BCHEACHEHPGDHTTRECQL
SCHEMBL207809 0.87 HPGD (0.53) BCHEACHEHPGDHTTRECQL
SCHEMBL206736 0.86 HPGD (0.48) HPGDMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL205931 0.84 TSHR (0.40) BCHEACHEHPGDMEN1KMT2A
SCHEMBL4084112 0.82 HPGD (0.45) HPGDMEN1KMT2AMAPK1NPC1
SCHEMBL205750 0.82 HPGD (0.39) HPGDMEN1KMT2AMAPK1
SCHEMBL205392 0.81 HPGD (0.46) HPGDKMT2AMAPTSMN1; SMN2
SCHEMBL206578 0.81 ALDH1A1 (0.45) HPGDKMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD BCHE 894/4885ACHE 2158/4885HPGD 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.